Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Torrent Pharmaceuticals is currently trading at Rs. 1343.75, up by 28.75 points or 2.19% from its previous closing of Rs. 1315.00 on the BSE.
The scrip opened at Rs. 1326.40 and has touched a high and low of Rs. 1356.75 and Rs. 1326.40 respectively. So far 2460 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1572.10 on 31-Mar-2017 and a 52 week low of Rs. 1143.50 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 1356.75 and Rs. 1300.05 respectively. The current market cap of the company is Rs. 22667.38 crore.
The promoters holding in the company stood at 71.25%, while Institutions and Non-Institutions held 18.52% and 10.24% respectively.
Torrent Pharmaceuticals (Torrent) has completed acquisition of branded formulation business of Unichem Laboratories (Unichem) for India and Nepal, including its Sikkim manufacturing facility, on a going concern basis by way of slump sale, on December 14, 2017. This transaction was in pursuance of the definitive binding agreement entered into between Torrent and Unichem on November 3, 2017.
From today, Torrent begins the integration of the Unichem business following the successful closure of its acquisition. The integration will aim to fuel and support strong growth of the acquired Unichem brands, consolidating speciality reach with a relentless focus on enhancing productivity. The acquisition will accelerate Torrent’s presence in the chronic space especially in the high growth segments of Indian Pharma market like Cardiology, Diabetology and Gastroenterology. Moreover, Unichem brings in an important new platform in Torrent’s sustainable growth strategy by expanding the company’s presence in the OTC segment.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1504.25 |
| Dr. Reddys Lab | 6263.70 |
| Cipla | 1406.25 |
| Zydus Lifesciences | 948.20 |
| Lupin | 1615.85 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
